(Reuters) – Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
(Reporting by Leroy Leo in Bengaluru)
Brought to you by www.srnnews.com